Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine

详细信息    查看全文

• 作者：Alina F. Dumitru MD^a ; Mohamed Shamji PhD^a ; Martin Wagenmann MD^b ; Simone Hindersin MD^b ; Kathrin Scheckenbach MD^b ; Jens Greve MD^c ; Thomas Klenzner MD^b ; Lorenzo Hess MSc^d ; Sabine Nebel PhD^e ; Christian Zimmermann PhD^e ; Catherine Zahner PhD^e ; Carsten B. Schmidt-Weber PhD^a ; ^f ; ^{csweber@tum.de"" rel=""nofollow} ; Adam M. Chaker MD^a ; ^b ; ^g
• 关键词：Randomized controlled trial ; allergic rhinitis ; nasal obstruction ; rhinomanometry ; IL-8 ; leukotriene B₄ ; histamine ; Ze 339 ; petasol butenoate complex ; Petasites hybridus ; desloratadine ; nasal allergen challenge
• 刊名：Journal of Allergy and Clinical Immunology
• 出版年：2011
• 出版时间：June 2011
• 年：2011
• 卷：127
• 期：6
• 页码：1515-1521.e6
• 全文大小：1071 K

文摘

Background

Allergic rhinitis symptoms of itching, sneezing, rhinorrhea, and nasal obstruction significantly decrease patients’ quality of life. Compared with histamine and leukotriene receptor antagonists, the petasol butenoate complex Ze 339 displays pharmacologically distinct properties. In vitro it inhibits the biosynthesis of leukotrienes and mediator release from activated eosinophils.

Objective

This study aimed to assess the efficacy and mode of action of Ze 339, desloratadine, and placebo on allergic rhinitis symptoms, nasal airflow, and local mediator levels after unilateral nasal allergen provocation.

Methods

In this double-blind, randomized, crossover study 18 subjects with allergic rhinitis to grass pollen received Ze 339, desloratadine, and placebo for 5 days before nasal allergen challenge with grass pollen extract. Rhinomanometry, symptom assessment, and local inflammatory mediator measurement were performed during the 24 hours after allergen challenge.

Results

With Ze 339, the patient’s time to recovery (5.4 ± 1.6 hours) from nasal obstruction after allergen challenge (time for return to 90 % of baseline value ± SEM) was significantly shorter than with placebo (9.1 ± 2.3 hours, P = .035) and desloratadine (10.7 ± 2.5 hours, P = .022). Likewise, Ze 339’s standardized symptom assessment for nasal obstruction (3.2 ± 1.3 hours) showed significantly faster relief (time for return to baseline value ± SEM compared with placebo, 8.3 ± 2.4 hours; P = .027) and desloratadine (4.5 ± 1.2 hours, P = .030). One interesting finding was that Ze 339 significantly reduced IL-8 and leukotriene B₄ levels in nasal secretions before challenge.

Conclusion

When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis.